# Draft for NewsForBC ## Working headline Viral ivermectin-and-mebendazole cancer study is real — but its own authors say it does not prove a cancer treatment ## Alternate headlines - New cancer paper reports patient-reported benefits from ivermectin and mebendazole, but evidence remains preliminary - Peer-reviewed study behind wellness ad calls findings “hypothesis-generating,” not proof of cancer cure - What a new Anticancer Research paper does — and does not — show about ivermectin, mebendazole and cancer ## Deck / subheadline A 2026 Anticancer Research paper followed 197 U.S. telemedicine patients using off-label compounded ivermectin and mebendazole. The reported results are striking, but the study had no control group, relied on self-reported outcomes, and all authors disclosed ties to The Wellness Company. ## Article draft A peer-reviewed cancer paper being promoted online as a breakthrough ivermectin-and-mebendazole study is real — but the study itself contains major limits that readers should understand before treating the findings as medical proof. The paper, published in the June 2026 issue of *Anticancer Research*, is titled *“Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”* It reports outcomes from 197 cancer patients who were prescribed a compounded capsule containing ivermectin and mebendazole through a U.S. telemedicine platform connected to The Wellness Company. The headline number used in online promotion is the study’s reported “clinical benefit ratio” of 84.4 per cent at six months. In the paper, that number combines patients who self-reported no current evidence of disease, tumour regression, or stable disease. Among the 122 participants who completed the six-month follow-up survey, 32.8 per cent reported no current evidence of disease, 15.6 per cent reported regression, 36.1 per cent reported stable disease, and 15.6 per cent reported progression. Those figures are attention-grabbing. But they are not the same as a randomized clinical-trial result. The study was observational, not randomized. It did not compare patients against a placebo group or a standard-treatment control group. Outcomes were self-reported by participants and were “not clinically adjudicated or radiographically confirmed,” according to the paper’s own limitations section. The authors also said confounding could not be excluded because many participants reported other treatments or interventions at the same time, including chemotherapy, radiation, surgery, supplements and dietary changes. The paper reports concurrent chemotherapy use in 27.9 per cent of participants, radiation in 21.3 per cent, surgery in 19.7 per cent, supplements in 49.2 per cent and dietary modification in 37.7 per cent. The paper’s conclusion is more cautious than the advertising language around it. The authors describe the findings as “hypothesis-generating” and say rigorous randomized, double-blind, placebo-controlled trials are needed to validate safety and efficacy, clarify dosing, and determine any role for the drug combination across specific cancer types. The conflict-of-interest disclosure is also central to the story. The paper states that all authors are affiliated with and/or receive salary support from The Wellness Company, which operates the telemedicine platform through which the ivermectin-mebendazole combination was prescribed and dispensed. The disclosure also says The Wellness Company offers compounded formulations of ivermectin and mebendazole as part of its clinical services. The study says no external funding was received. For B.C. readers, the practical takeaway is caution. The paper may be a legitimate research signal worth further study, but it does not establish ivermectin and mebendazole as a proven cancer therapy. Patients should not stop, delay, or replace oncology care based on online ads, social media clips, or a single observational paper. The U.S. National Cancer Institute advises patients to discuss complementary and alternative medicine with their health-care team, especially because supplements or non-standard products can interact with cancer treatments or cause harm. BC Cancer also maintains public information on complementary and alternative therapies for patients navigating cancer care. The study is available through *Anticancer Research* and PubMed under DOI 10.21873/anticanres.18194 and PubMed ID 42203321. ## Key facts box - Study: *Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort* - Journal: *Anticancer Research*, June 2026, 46(6): 3243–3255 - DOI: 10.21873/anticanres.18194 - PMID: 42203321 - Study type: prospective observational cohort / clinical program evaluation - Baseline participants: 197 - Six-month follow-up: 122 participants, or 61.9 per cent - Reported clinical benefit ratio: 84.4 per cent among follow-up respondents - Major limitation: no control group; self-reported outcomes; no radiographic or clinical adjudication - Conflict disclosure: all authors affiliated with and/or salary-supported by The Wellness Company ## Editorial caution / legal-medical note This story should not provide dosing, treatment instructions, or “where to get it” details. Keep it framed as public-interest health-literacy reporting: what the paper says, what the paper does not prove, and why patients should discuss non-standard therapies with qualified oncology professionals. ## Suggested social post A viral wellness ad points to a real peer-reviewed paper on ivermectin + mebendazole in cancer patients. But the study was observational, self-reported, had no control group, and its own authors call the findings “hypothesis-generating.” Our plain-language breakdown: [link] ## Source trail - Anticancer Research article page: https://ar.iiarjournals.org/content/46/6/3243 - PDF: https://ar.iiarjournals.org/content/anticanres/46/6/3243.full.pdf - PubMed: https://pubmed.ncbi.nlm.nih.gov/42203321/ - DOI: https://doi.org/10.21873/anticanres.18194 - NCI complementary and alternative medicine overview: https://www.cancer.gov/about-cancer/treatment/cam - BC Cancer complementary and alternative therapies page: https://www.bccancer.bc.ca/health-info/coping-with-cancer/complementary-alternative-therapies